Automated Clinical Trial Monitoring: Capturing the Site Visit, and the Data Between Visits

A clinical trial is validated largely on paper. The assessment happens in the room, and what survives is what the rater writes down afterward: a score, a short note, a checkbox. The visit itself, how the assessment was actually administered and how the participant actually presented, is rarely observed by anyone outside that room. For data that decides whether a drug works, that is a great deal to take on trust.

Automated clinical trial monitoring changes what a sponsor can see. Using video-based, multimodal AI, it monitors the site visit as it happens, turning the encounter itself into an objective, reviewable record. And because the technology does not depend on the clinic, the same monitoring continues after the visit ends, capturing data across the long stretches between appointments. The result is visibility into both halves of a trial that usually run unobserved.

Monitoring the visit as it happens

Start with the visit, because that is where the primary data is made. When an assessment is captured on video and analyzed by multimodal AI, the record is no longer limited to a rater’s summary. The participant’s facial expression, vocal qualities, speech patterns, and behavior are all captured directly, which is especially relevant for the movement, mood, and behavioral endpoints common in CNS and behavioral health trials.

That objective record does two things at once. It strengthens the endpoint data, because the measurement no longer varies with who administered the scale or how practiced they happen to be. And it creates a verifiable account of the visit that can be reviewed against the same standard every time, rather than reconstructed from notes after the fact. Assessor variance, one of the quiet drivers of noise and inflated sample sizes in trials, narrows when the same assessment is measured the same way across every rater and every site.

Fidelity you can see, not infer

Monitoring the visit also makes protocol fidelity visible while the trial is running. Was the assessment administered the way the protocol specifies? Did the visit follow the sequence it was supposed to? In a paper-based model, those questions get answered weeks later through source data verification, after any deviation has already worked its way into the data. When the visit itself is monitored, drift surfaces while there is still time to correct it, whether it is a single rater developing a habit or a site sliding out of alignment with the protocol.

Caught early, a deviation is a coaching conversation. Caught late, it is a data point to explain or exclude. Across hundreds of visits, that difference decides how clean the final dataset is.

Monitoring that does not stop at the clinic door

The visit is the anchor, but it is not the whole trial. Most of a participant’s time is spent away from the site, and in a visit-only model that time is invisible. Adherence drifts, symptoms shift, and early signals go unrecorded until the next appointment, if they are captured at all.

The same technology that monitors the visit can keep monitoring between visits. Short, structured remote follow-ups capture data outside the clinic, filling the gaps a visit schedule leaves open and adding context the next appointment would otherwise miss. This is the direction regulators are encouraging. The FDA’s final guidance on digital health technologies for remote data acquisition in clinical investigations describes how sponsors can collect participant data remotely between visits. In-visit and between-visit monitoring together give a continuous view of a trial rather than a series of disconnected snapshots.

More signal, not more burden

The instinct when a trial needs better data is to add procedures. The evidence suggests that instinct is misplaced. A TransCelerate and Tufts Center for the Study of Drug Development analysis found that up to 32.5% of the per-patient data collected in Phase III trials comes from procedures not directly supporting the primary or key secondary endpoints, and that these non-core procedures account for 25 to 30% of the burden carried by participants and sites. More assessments tend to add burden faster than insight.

Automated monitoring works differently. It draws objective signal from the visit that already happens and adds structured signal between visits, rather than expanding the procedure list at the site. The data gets richer while the burden on participants and coordinators does not.

From trial evidence to safety obligations

The value of objective, continuous monitoring does not end at submission. It extends into the obligations that follow approval. Risk Evaluation and Mitigation Strategies (REMS), the FDA’s safety programs for drugs with serious risks, can require ongoing patient monitoring, registry enrollment, documentation of safe-use conditions, and periodic assessment of whether the program is working.

Those are data-collection and patient-monitoring problems, which is exactly what this capability is built to handle. The same in-visit and between-visit monitoring that strengthens a trial can support the structured patient monitoring and documentation a REMS program calls for after approval. A sponsor that builds this capability during development is already positioned for the safety obligations that come next, rather than standing up a separate system to meet them later.

A faster path to a complete picture

Delays in a development program often trace back to the same few causes: missing data, protocol deviations, and the reconciliation work required to clean both up. Monitoring the visit and the time around it reduces all three. An objective in-visit record means fewer questions at analysis. Visible fidelity means fewer deviations to explain. Continuous between-visit data means fewer gaps to reconcile.

The payoff is a more complete evidence package, assembled with less scrambling at the end, which shortens timelines and helps effective therapies reach the patients waiting for them sooner. Throughout, Videra Health’s role is as a neutral, evidence-generation partner: the capability supports objective clinical assessment and robust evidence, not commercial outcomes.

What it looks like in practice

The case for objective, low-friction monitoring is not only theoretical. When a top-20 global pharmaceutical sponsor replaced a failing legacy assessment vendor mid-study, an intuitive, AI-powered approach restored site investigator confidence and resumed enrollment across all 45 sites, while enabling novel AI-driven endpoints the prior system could not. The lesson is direct: when monitoring fits how sites and participants actually work, the data improves and the trial keeps moving. It is the same principle behind Videra’s work on multimodal AI assessment in clinical trials.

Getting started

For sponsors weighing how to see more of their trial, both inside the visit and beyond it, automated monitoring is built to add visibility rather than overhead. It captures the visit as an objective record, makes protocol fidelity visible while there is still time to act, and keeps monitoring between appointments, producing the kind of complete, objective evidence that holds up from submission through post-approval safety obligations.

The clearest way to see whether it fits a given program is to see it work.